Company NewAmsterdam Pharma Company N.V. Nasdaq

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for NewAmsterdam Pharma Company N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
18.02 ^USD	+4.59%		-6.10%	+61.33%

11/06	NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	MT
10/06	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimerâs disease. The Company strives to offer its products around the world.

USD in Million	2022	Weight	2023	Weight	Delta
Transformative Therapies for Cardio-metabolic Diseases 100.0 %	102	100.0 %	15	100.0 %	-85.13%

USD in Million	2022	Weight	2023	Weight	Delta
Italy 100.0 %	102	100.0 %	15	100.0 %	-85.13%

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	89,976,538	84,841,876 ( 94.29 %)	0	94.29 %

Name	Equities	%	Valuation
Frazier Life Sciences Management LP 13.59 %	12,226,943	13.59 %	229 M $
Forbion Capital Partners Management Holding BV 13.15 %	11,831,461	13.15 %	222 M $
Bain Capital Life Sciences LP 11.64 %	10,473,913	11.64 %	196 M $
Viking Global Investors LP 8.918 %	8,024,565	8.918 %	150 M $
RA Capital Management LP 8.739 %	7,864,000	8.739 %	147 M $
AMGEN INC. 5.456 %	4,910,000	5.456 %	92 M $
Morningside Group Ltd. 4.513 %	4,060,923	4.513 %	76 M $
Medicxi Ventures (Jersey) Ltd. 3.189 %	2,869,565	3.189 %	54 M $
Adage Capital Partners GP LLC 2.028 %	1,824,601	2.028 %	34 M $
BVF, Inc. 1.691 %	1,521,948	1.691 %	29 M $

Name	Equities	%	Valuation
Frazier Life Sciences Management LP -	500,333	-	4 M $
RA Capital Management LP -	333,333	-	3 M $
Affinity Asset Advisors LLC -	202,599	-	2 M $
GTS Securities LLC -	121,150	-	957 085 $
Bain Capital Life Sciences LP -	100,000	-	790 000 $
Deerfield Management Co. LP (Private Equity) -	92,787	-	733 017 $
Monashee Investment Management LLC -	31,189	-	246 393 $
HRT Financial LLC -	30,321	-	239 536 $
Laurion Capital Management LP -	16,666	-	131 661 $
Vestcor, Inc. -	9,632	-	76 093 $

NewAmsterdam Pharma Co. NV

Gooimeer 2-35

1411 DC, Naarden

+31 35 206 2971

http://www.newamsterdampharma.com

address NewAmsterdam Pharma Company N.V.(NAMS)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.87 EUR

Average target price

35.13 EUR

Spread / Average Target

+108.26%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.91%	11TCr
ARGENX SE	+8.24%	2.36TCr
BIONTECH SE	-19.80%	2.04TCr
GENMAB A/S	-16.19%	1.65TCr
BEIGENE, LTD.	-13.45%	1.64TCr
WUXI APPTEC CO., LTD.	-44.35%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+66.67%	1.52TCr
NEUROCRINE BIOSCIENCES, INC.	+2.13%	1.35TCr

Bio Therapeutic Drugs